Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Argus Health
US Army
Mallinckrodt
Chinese Patent Office
Colorcon

Generated: September 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,952,015

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,952,015
Title:Inhibitors of Bruton's tyrosine kinase
Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk, such as those having the structure of Formula (A) ##STR00001## Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Inventor(s): Honigberg; Lee (San Francisco, CA), Verner; Erik (Belmont, CA), Pan; Zhengying (Austin, TX)
Assignee: Pharmacyclics, Inc. (Sunnyvale, CA)
Application Number:12/907,759
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,952,015
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 8,952,015

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pharmacyclics Inc IMBRUVICA ibrutinib CAPSULE;ORAL 205552-002 Dec 20, 2017 RX Yes No   Try a Free Trial   Try a Free Trial TREATMENT OF WALDENSTROM'S MACROGLOBULINEMIA   Try a Free Trial
Pharmacyclics Inc IMBRUVICA ibrutinib CAPSULE;ORAL 205552-002 Dec 20, 2017 RX Yes No   Try a Free Trial   Try a Free Trial TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA   Try a Free Trial
Pharmacyclics Inc IMBRUVICA ibrutinib CAPSULE;ORAL 205552-002 Dec 20, 2017 RX Yes No   Try a Free Trial   Try a Free Trial TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA   Try a Free Trial
Pharmacyclics Inc IMBRUVICA ibrutinib CAPSULE;ORAL 205552-002 Dec 20, 2017 RX Yes No   Try a Free Trial   Try a Free Trial TREATMENT OF MARGINAL ZONE LYMPHOMA   Try a Free Trial
Pharmacyclics Inc IMBRUVICA ibrutinib CAPSULE;ORAL 205552-002 Dec 20, 2017 RX Yes No   Try a Free Trial   Try a Free Trial TREATMENT OF MANTLE CELL LYMPHOMA   Try a Free Trial
Pharmacyclics Inc IMBRUVICA ibrutinib CAPSULE;ORAL 205552-001 Nov 13, 2013 RX Yes Yes   Try a Free Trial   Try a Free Trial TREATMENT OF MARGINAL ZONE LYMPHOMA   Try a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,952,015

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 531263   Try a Free Trial
Australia 2006348662   Try a Free Trial
Australia 2008232762   Try a Free Trial
Australia 2010201052   Try a Free Trial
Australia 2012205166   Try a Free Trial
Brazil PI0622054   Try a Free Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Healthtrust
Johnson and Johnson
Queensland Health
AstraZeneca
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.